On July 24, 2026, Ed Silverman published a Pharmalot column summarizing recent personnel moves in the pharmaceutical sector. The story called out a specific executive appointment: Rigel Pharmaceuticals appointed Alison Hannah as executive vice president and chief medical officer. The article is a Pharmalot item that also invites industry readers to submit notices of hires, promotions, and filled positions for future columns.
The column reports that Rigel Pharmaceuticals has hired Alison Hannah into the combined role of executive vice president and chief medical officer. The article notes Hannah’s immediate prior position was the same title at CytomX Therapeutics.
The source presents these facts concisely but does not expand on Hannah’s background beyond the previous employer and title. No additional corporate commentary, strategic rationale, or quotes from Hannah or Rigel were included in the published excerpt.
What the source reported:
What the source did not report (details not provided in the article):
Because these items were not included in the source, they cannot be inferred or supplied here.
The Pharmalot column includes an open invitation for readers and industry contacts to submit notices of personnel changes. The author explicitly encourages readers to share news of new hires, promotions, and hard-to-fill role resolutions so the column can highlight them. The article states, in direct terms, that readers should send their changes and the column will find a place for them.
The piece does not provide a detailed submission form or a public step-by-step process in the excerpt; however, the author’s email address appears on the page, which is presented as the contact route for contributions.
Ed Silverman is identified on the page as the Pharmalot columnist and a senior writer for STAT. The author’s remit, as described on the page, includes coverage of prescription drug pricing, affordability and access, patents, litigation, and legislation. The Pharmalot column functions as a regular industry feature that highlights hires, departures, and promotions in biotech and pharma.
The article includes the author’s contact email (ed.silverman@statnews.com) and links to the Pharmalot and STAT+ newsletter offerings tied to Silverman’s reporting.
The page clearly indicates the item is a STAT+ exclusive and invites readers to unlock the remainder of the story and associated premium content by subscribing. The article displays promotional pricing and plan options for STAT+: monthly and annual tiers are shown on the page alongside group subscription options. The remainder of the reported piece beyond the excerpt provided is behind the STAT+ paywall.
The article page is embedded within STAT’s broader biotech and pharma coverage. The page links to related Pharmalot and STAT+ items, including other Pharmalot posts and subscriber-only articles. It also provides navigation to newsletters, events, and trackers maintained by STAT. These navigational and promotional elements are part of the article page but do not supply additional factual detail about the Rigel appointment.
This rewrite adheres strictly to the facts presented in the source. Details that the source text did not report — for example, Hannah’s start date, prior roles beyond CytomX, compensation, and corporate commentary — are explicitly noted as not reported and therefore not included here. The fuller STAT+ article content beyond the excerpt was inaccessible in the provided source.